In Healthcare, High Tech Gets a Taste of Its Own Disruption

By Kristen Schepker

Over the last five years, nearly all of the major information technology companies have launched some sort of healthcare initiative. The COVID pandemic, with its surging demand for telemedicine and rapid exchange of medical data, only intensifed that trend.

But some tech giants have learned the hard way that healthcare is very different from other business sectors.

High-profile failures like the demise of Haven — a nonprofit healthcare organization formed by Amazon in partnership with JP Morgan Chase and Berkshire Hathaway — are cautionary tales, showing that the creative disruptions that proved so successful in retail, transportation, and financial services can crash and burn in the medical sphere.

[ ...Read More ]

Featured Articles

Managing “Mitochondriopathy” For Healthier Aging

Written by Erik Goldman

What is the common theme underlying nearly all of the diseases associated with aging? Mitochondrial dysfunction. It is a simple biological fact that mitochondrial function tends to decline with age.  This affects every organ and every tissue in the body. But clinicians often fail to consider “mitochondriopathy” as they treat the various diseases that their […]

[ ...Read More ]

In Healthcare, High Tech Gets a Taste of Its Own Disruption

Written by Kristen Schepker

Over the last five years, nearly all of the major information technology companies have launched some sort of healthcare initiative. The COVID pandemic, with its surging demand for telemedicine and rapid exchange of medical data, only intensifed that trend. But some tech giants have learned the hard way that healthcare is very different from other […]

[ ...Read More ]

HPC Video

Improving Clinical Outcomes with Paraprobiotics

Written by Erik Goldman

Paraprobiotics could be just what your patients need for a better life. Pre- and probiotics have become mainstream solutions for improved overall wellbeing, but research has revealed that paraprobiotics–heat-killed probiotic strains–can also have very specific benefits. Paraprobiotics also deliver the added advantage of a longer shelf-life without the need for refrigeration.

In this free webinar, Danielle Citrolo, PharmD, and Shintaro Ichikawa, PhD, will discuss how paraprobiotics will benefit your patients. They will introduce you to IMMUSE and EYEMUSE, two branded forms of clinically studied strains that help to bolster immune function and vision by stimulating immune cells within the gut and the retina. IMMUSE is currently supported by eleven human trials and EYEMUSE is supported by two studies.

In this webinar, you will:

  • Gain an understanding of what are paraprobiotics, and why they could be a good alternative to probiotic strains in your practice.
  • Learn the importance of the immune system and its role in overall health. 
  • Understand the ability of paraprobiotics to influence the immune system for improved health outcomes.
  • Learn about the published clinical research behind the unique paraprobiotic strains used for IMMUSE and EYEMUSE.

SPONSORED BY KYOWA HAKKO USA

Danielle Citrolo, PharmD is a registered pharmacist who provides scientific and regulatory support to Kyowa’s customers in the US, Canada and Latin America. She holds degrees in biochemistry and chemistry from North Carolina State University and a Doctor of Pharmacy from Albany College of Pharmacy, NY.

Shintaro Ichikawa, PhD, is the Director of Technical Affairs at Kyowa Hakko USA. He is leading the launch of IMMUSE™, the company’s unique Lactococcus lactis strain, in the United States. He previously led the launch of IMMUSE™ in Japan. Dr. Ichikawa holds a Doctorate in Life Science from the University of Tokyo, Department of Applied Biochemistry.

[ ...Read More ]